Similar Search Results

Quality of Life in Patients with Epilepsy and Impact of Treatments

Berto, Patrizia - In: PharmacoEconomics 20 (2002) 15, pp. 1039-1059

Epilepsy is a chronic condition with numerous social and psychological consequences. This work aimed to review … available data on epilepsy and the impact of surgical and pharmaceutical treatments on the quality of life in adults and … children. Research on quality of life in epilepsy is characterised by a wide and fragmentary range of methodology, both in …

Persistent link: https://www.econbiz.de/10005449230

The Cost Effectiveness of Two New Antiepileptic Therapies in the Absence of Direct Comparative Data: A First Approximation

van Hout, Ben A.; Gagnon, Dennis D.; Mcnulty, Pauline; … - In: PharmacoEconomics 21 (2003) 5, pp. 315-326

lamotrigine) for epilepsy that have been assessed in clinical trials against placebo. Methods: Without head to head comparative … lamotrigine with placebo. Results: Assuming that the `proportionality assumption' holds for the medical treatment of epilepsy, and …

Persistent link: https://www.econbiz.de/10005404957

Use of Surgical Procedures in the Treatment of Epilepsy: Interventions and Outcomes

Langfitt, John T.; Bronstein, Kathryn - In: Disease Management and Health Outcomes 5 (1999) 1, pp. 23-40

Medically intractable epilepsy (MIE) is a chronic disabling condition that primarily affects the young. Inadequately …

Persistent link: https://www.econbiz.de/10005590087

Physician Financial Incentives in Managed Care: Resource Use, Quality and Cost Implications

Armour, Brian S.; Pitts, Mmelinda - In: Disease Management and Health Outcomes 11 (2003) 3, pp. 139-147

Patients with health insurance do not make the most cost conscious healthcare decisions since they bear only a fraction of the total cost of medical care. Managed care advocates point to financial incentives as a way to reduce wasteful resource use. However, physicians with managed care...

Persistent link: https://www.econbiz.de/10005242991

Economic Implications of the Use of Basiliximab in Addition to Triple Immunosuppressive Therapy in Renal Allograft Recipients: A UK Perspective

Walters, Stephen J.; Whitfield, Malcolm; Akehurst, Ronald L. - In: PharmacoEconomics 21 (2003) 2, pp. 129-138

Objective: To compare resource use and costs in renal transplant recipients treated with basiliximab or placebo plus triple immunosuppressive therapy. Design: International randomised, double-blind, placebo-controlled trial; economic evaluation undertaken alongside the efficacy trial. The...

Persistent link: https://www.econbiz.de/10005243136

Resource Utilisation and Cost Analysis of Memantine in Patients with Moderate to Severe Alzheimer's Disease

Wimo, Anders; Winblad, Bengt; Stoffler, Albrecht; … - In: PharmacoEconomics 21 (2003) 5, pp. 327-340

Background: Alzheimer's disease (AD) is a devastating illness that causes enormous emotional stress to affected families and is associated with substantial medical and nonmedical costs. Objective: To determine the effects of 28 weeks of memantine treatment for patients with AD on resource...

Persistent link: https://www.econbiz.de/10005243181

Burden of Illness in Irritable Bowel Syndrome Comparing Rome I and Rome II Criteria

Badia, Xavier; Mearin, Fermin; Balboa, Agustin; Baro, Eva; … - In: PharmacoEconomics 20 (2002) 11, pp. 749-758

Objectives: To evaluate the burden of illness in irritable bowel syndrome (IBS), in terms of resource utilisation (direct and indirect) and health-related quality of life (HR-QOL), in individuals with IBS who meet Rome I and Rome II criteria. Methods: A cross-sectional study, carried out by...

Persistent link: https://www.econbiz.de/10005243189

An Economic Overview of Chronic Obstructive Pulmonary Disease

Ruchlin, Hirsch S.; Dasbach, Erik J. - In: PharmacoEconomics 19 (2001) 6, pp. 623-642

Chronic obstructive pulmonary disease (COPD) is a major cause of mortality and morbidity. Relatively few pharmacoeconomic studies have been conducted on this disease. This article reviews available information about the utilisation of healthcare resources and cost of care, and the cost or cost...

Persistent link: https://www.econbiz.de/10005243194

Economic Burden of Chronic Obstructive Pulmonary Disease: Impact of New Treatment Options

Friedman, Mitchell; Hilleman, Daniel E. - In: PharmacoEconomics 19 (2001) 3, pp. 245-254

The incidence, morbidity and mortality of chronic obstructive pulmonary disease (COPD) is rising throughout the world. The total economic cost of COPD in the US in 1993 was estimated to be over $US15.5 billion, with $US6.1 billion for hospitalisation, $US4.4 billion for physician and other fees,...

Persistent link: https://www.econbiz.de/10005243216

Management of Pharmaceutical Resources for the Primary Prevention of Coronary Heart Disease in Catalonia (Spain) Based on Efficiency and Equity

Plans-Rubio, Pedro - In: Disease Management and Health Outcomes 9 (2001) 9, pp. 495-506

Objective: The objective of the study was to develop a procedure to distribute health resources among treatments for the primary prevention of coronary heart disease based on efficiency and equity. Design and Setting: Two procedures to manage pharmaceutical resources for the primary prevention...

Persistent link: https://www.econbiz.de/10005448756